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Pharmacokinetics of oral micronized -estradiol in postmeno- Although appropriate indications for estrogen replace-
pausal women receiving maintenance hemodialysis. ment therapy are controversial, 11% of women with end-
Background. Although 11% of postmenopausal women
stage renal disease (ESRD) over 45 years of age are treatedwith end-stage renal disease (ESRD) are prescribed hormone
with estrogen replacement therapy [1]. Previous reportsreplacement therapy (HRT), the appropriate use remains poorly
explored. Although there remains controversy surrounding the have suggested that renal failure may alter the pharmaco-
benefits of HRT, it may be of particular interest in this popula- kinetics of estrogen. Ginsburg et al [2] reported that aftertion, which has a high risk of bone loss and a fourfold increase
a single dose of estradiol, serum concentrations of estra-in fracture risk compared to the general population. However,
the appropriate dose of estrogen for use in postmenopausal diol and estrone were two to three times that of the
women with ESRD is not known. The objective of this study control, while another investigator reported that urinary
was to evaluate the steady-state pharmacokinetics of oral mi-
excretion of estradiol in men with normal renal functioncronized -estradiol in postmenopausal women with ESRD
compared with postmenopausal women with normal renal was 78% to 83% over four days compared to 1.4% in men
function in order to determine equivalent dosing. with ESRD [3]. Inappropriately high doses of hormone
Methods. Six postmenopausal women with ESRD receiving
replacement therapy may result in high levels of estrogenmaintenance hemodialysis and 6 healthy postmenopausal con-
and contribute to the higher risk for endometrial cancertrols received 14 days of micronized -estradiol (1.0 mg for
control, 0.5 mg for ESRD). Blood, urine, and dialysate samples that has been reported among women with ESRD [4, 5].
were obtained during a dosage interval on day 14. Estradiol, Other potential risks of estrogen, such as breast cancer,
estrone, albumin, and sex-hormone binding globulin (SHBG)
coagulopathy, or risk of coronary artery disease, may alsoconcentrations were determined. Free estradiol concentrations
were calculated using a previously described method. be dose-dependent. Although single dose pharmacokinetic
Results. Women with ESRD had significantly lower serum studies have suggested dose modification may be neces-
albumin (610  31 mol/L vs. 684  83mol/L) and SHBG
sary, the steady-state pharmacokinetics of estradiol in(78  17 vs. 118  13 nmol/L) than control subjects. Total
women with ESRD have not been studied. If estradiolclearance of estradiol was not significantly different. Due to
difference in binding, free estradiol concentrations were sig- undergoes nonlinear metabolism or protein binding, the
nificant higher in ESRD women (53.2  17.7 pg/mL) than single dose study may underestimate the effects of ESRD
control women (43.5  8.7 pg/mL), despite receiving 50%
and overestimate the determination of an equivalent doseof the dose. There was no significant difference in estrone
concentrations. Clearance of both estradiol and estrone in the of HRT in ESRD postmenopausal women. Given the re-
dialysate was minimal. cent reports suggesting a slightly higher risk for cardiovas-
Conclusion. Women with ESRD should receive approxi-
cular events among women treated with hormone replace-mately 50% of the dose typically prescribed to women without
ment therapy (HRT), determining the appropriate doseESRD.
of estrogen replacement is particularly important in the
ESRD population [6]. Therefore, the objective of the
Key words: hemodialysis, hormone replacement therapy, pharmacoki-
study was to determine the steady-state pharmacokineticsnetics.
of oral micronized -estradiol in postmenopausal women
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METHODS concentrations were calculated using a log-linear scale.
Estrone concentrations in serum, urine, and dialysateStudy population
fluids were determined at each of the blood sampling
Six postmenopausal females with ESRD receiving time points by an enzyme immunoassay (ALPCO, Wind-
maintenance hemodialysis at the Northwest Kidney Cen- ham, NH, USA). The standard curve ranged from 25 to
ter, Seattle, Washington, and six postmenopausal females 2000 pg/mL and sample concentrations were calculated
with normal renal function (controls) were recruited using a log-linear scale. Samples for both estradiol and
from a University of Washington General Internal Medi- estrone were diluted sufficiently with assay buffer as
cine Clinic, Seattle, Washington, to participate in the needed in order to obtain the concentrations within the
study. Women with ESRD and controls were approxi- standard curve. Serum concentrations of albumin (Sigma
mately matched for age (within 3 years) and body mass Diagnostics, St. Louis, MO, USA) and SHBG (Wako
index [weight (kg)/height (cm2)]  15%. Hemodialysis Diagnostics, Richmond, VA, USA) were determined at
patients were required to have been stable dialysis pa- one time point per subject and assayed by a quantitative,
tients for greater than 6 months. Nondialysis patients colorimetric method.
had a serum creatinine of 1.4 mg/dL. All subjects were
required to have had their last menstrual period more Data analysis
than 1 year prior to enrollment, a follicle stimulating Serum concentration of unbound or free estradiol
hormone (FSH) level greater than 40 mIU/mL, normal (EEu) was calculated from total serum estradiol concen-
serum transaminases, and a normal Pap smear and mam- trations (EE), albumin (ALB), and SHBG plasma con-
mogram within 1 year of enrollment. Subjects were ex- centrations as previously described by Ginsburg et al [2]
cluded if they were currently receiving estrogen therapy, using the following equation:
had active liver disease, a history of deep vein thrombo-
EEu sis, a history of breast cancer, a hematocrit less than
27%, or diabetes mellitus requiring insulin. EE 0.003571
[(3.14 108 SHBG) (4.21 104ALB 100) 1]Study design
All subjects were treated with micronized -estradiol
(Estrace) (1.0 mg for control and 0.5 mg for ESRD Serum total and unbound estradiol concentration ver-
subjects) for 14 days and medroxyprogesterone acetate sus time data were analyzed with noncompartmental
(MPA) 2.5 mg/day. On day 14, the subjects were admit- analysis using standard pharmacokinetic methodology.
ted for monitoring to the Clinical Research Unit at the Area under the concentration-time curve during a steady-
University of Washington. Intravenous access was estab- state interval (AUCss) was calculated using the trapezoi-
lished for blood sampling. Baseline serum assays were dal rule. The average steady-state serum concentration
obtained and 24-hour urine collection was initiated. A (Cavg) was calculated as the ratio of AUCss to the dosage
1.0 mg dose for control and 0.5 mg dose for ESRD interval. Steady-state oral clearance (Cl/F) was calcu-
subjects of micronized -estradiol and 2.5 mg MPA was lated as the ratio of daily dose to AUCss. The fraction
administered orally. Standard four-hour hemodialysis of estradiol excreted (Fe) in the urine was determined
for subjects with ESRD was initiated at hour four. as the ratio of amount of unchanged estradiol recovered
Among dialysis patients, dialysate samples were col- in the urine during the dosage interval to the interval
lected at 10, 60, 120, 180, and 240 minutes after the start dose. The renal clearance (Clr) was determined as the
of dialysis. Blood samples were collected at hour 0, 1, 2, product of Fe and Cl/F. The dialysis clearance (ClD) of
4, 9, 12, 16, and 24 postdose. Blood samples were drawn estradiol and estrone was determined as the ratio of
and spun for serum separation. Serum, urine, and dialy- the amount excreted during the 5-hour dialysate to the
sate specimens were frozen at 20	C for storage. After midpoint plasma concentration of estradiol or estrone,
the hour 24 sample the study subjects were discharged respectively. Two-sided unpaired t test was used to com-
from the hospital. pared the serum concentrations of albumin and SHBG
and the pharmacokinetic parameters between healthyAssays
control and ESRD subjects at the P  0.05 level of
Estradiol, estrone, albumin, and sex-hormone binding significance.
globulin (SHBG) were assayed using commercially avail-
able kits. Estradiol concentrations in serum, urine, and
RESULTSdialysate fluids were determined at each of the blood
sampling time points using a competitive immunoassay Characteristics of the study population are given in
Table 1. Age, weight, and serum albumin were similar(Assay Designs, Inc., Ann Arbor, MI, USA). The stan-
dard curve ranged from 9.6 to 30,000 pg/mL, and sample between women with and without ESRD. Women with
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Table 1. Subject characteristics
Control ESRD
(1 mg) (0.5 mg) P value
Age years 5310 6311 0.13
Weight kg 26.43.1 25.33.7 0.54
Albumin lmol/L 68483 61031.4 0.088
SHBG nmol/L 11824 7817 0.011
Abbreviations are: ESRD, end-stage renal disease; SHBG, sex-hormone bind-
ing globulin.
Fig. 2. Estrone serum concentrations obtained at steady state during
one dosage interval for ESRD and healthy control subjects. Mean 
standard deviations are plotted.
Fig. 1. Estradiol serum concentrations obtained at steady state during
one dosage interval for ESRD and healthy control subjects. Mean 
standard deviations are plotted.
ESRD had significantly lower SHBG than women with-
out ESRD. All women with ESRD had residual renal
function.
The total estradiol and estrone serum concentrations
Fig. 3. Free estradiol serum concentrations obtained at steady stateduring a steady-state dosage interval for control and during one dosage interval for healthy control subjects and ESRD
ESRD subjects are shown in Figures 1 and 2, respec- subjects. Mean  standard deviations are plotted.
tively. In the healthy control subjects, serum concentra-
tions of estradiol exhibited a secondary peak within the
24-hour dosage interval, which was not noted in the patients. However, the total clearance of estradiol was
ESRD subjects. The average steady serum concentration not significantly different due to the small fraction of
of estradiol was approximately the same in women with estradiol excreted unchanged by kidneys in both the
ESRD compared to controls, in spite of having received ESRD and control women. Clearance of estradiol and
one-half less estradiol. In spite of receiving one-half the estrone during dialysis was also minimal, with less than
daily dose of estradiol, average steady-state concentra- 2% of the dose of estradiol excreted as estradiol and
tions of estrone were similar but variable, and free estra- estrone. The fraction of estradiol and estrone excreted
diol serum concentrations were higher in the ESRD sub- unchanged in the urine and dialysate was less than
jects than in the healthy control subjects. 0.001% of the estradiol dose for the control and renal
The unbound or free estradiol serum concentrations dialysis patients.
are depicted in Figure 3. The higher free estradiol con-
centrations are predominately due to the significantly
DISCUSSIONlower serum concentrations of SHBG and a trend toward
lower albumin concentration (Table 2). There was sig- The free estradiol serum concentrations among post-
menopausal women with ESRD were more than 20%nificantly decreased renal clearance of estradiol in ESRD
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Table 2. Mean standard deviation (and range) of pharmacokinetic parameters
Control ESRD
1 mg 0.5 mg P value
Estradiol Cl total mL/min/kg 367106 (233–492) 279163 (155–504) 0.30
Estradiol Cavg pg/mL 28.66.6 (23.5–41.4) 23.49.7 (11.1–34.4) 0.35
Free estradiol Cavg pg/mL 0.440.09 (0.35–0.62) 0.530.18 (0.19–0.67) 0.03
Estrone Cavg pg/mL 376338 (118–910) 373325 (159–977) 0.99
Estradiol
Cl renal mL/min/kg 0.0570.0052 0.00150.002 0.035
ClD dialysis mL/min/kg NA 0.100.06
Estrone
ClD dialysis mL/min/kg NA 0.530.845
Cl is clearance; Cavg is average serum concentration; ClD is dialysis clearance.
higher than among control women, despite the reduction that the concentration of SHBG is increased by oral
estradiol in all women, and simply increased to a lesserin dose of -estradiol of 50%. It is likely that the higher
steady-state levels of estrogen are due to decreased catab- extent in the ESRD patients. Further studies are needed
to determine if women with ESRD have subnormal syn-olism of estradiol. Data suggest that estrogen is metabo-
lized by the liver, metabolites are excreted in the urine, thetic rates of SHBG.
Our data suggest that dosing modifications are neces-and that clearance is delayed in ESRD patients [3].
Among women with ESRD, this secondary peak in sary among women with ESRD. Inappropriately high
doses of hormone replacement therapy may contributethe estradiol concentration time curve did not occur.
Estradiol undergoes extensive first-pass metabolism in to the higher risk for endometrial cancer, an estrogen-
dependent cancer, reported among women with ERSDthe liver to the less active estrone and estriol [7]. There
is also significant enterohepatic recirculation, which may [4]. It is also possible that inappropriately high doses of
estrogen may place women at higher risk for thrombosis.explain the secondary peak in the estradiol concentration
time curve seen in the control population [7]. A potential Hormone replacement therapy has been associated with
a higher risk for venous thrombosis [12] and may induceexplanation may be decreased enterohepatic recircula-
tion among women with ESRD. a hypercoaguable state [13]. A hypercoagulable state
may lead to an increased risk of vascular access thrombo-Both the control and women with ESRD women were
treated with concomitant MPA and estrogen. Therefore sis and pulmonary embolus, both complications for which
ESRD patients are at particularly high risk. Other riskswe were not able to rule out an interaction between
ESRD, estradiol, and MPA. However, the results of the of estrogen therapy include breast cancer, increased inci-
dence of coronary artery disease [6], and gallstones [14].study remain clinically relevant since the use of combina-
tion therapy is standard care among women with an Although dose-response data on these risks are limited,
it is plausible that higher doses would increase the risks.intact uterus.
After two weeks of treatment in our study, the women The use of hormone replacement therapy among
women without ESRD has become increasingly contro-with ESRD had lower SHBG than the control women.
Prior reports have had seemingly conflicting results. Sev- versial. The recent report from the Women’s Health
Initiative (WHI) has documented significant reductionseral studies in postmenopausal women with normal renal
function have shown an increase in SHBG concentration in hip fracture and colorectal cancer rates among post-
menopausal women [6]. Although estrogens have beenof about 45% with oral estradiol after 3 months, but
transdermal or vaginal routes of delivery do not raise reported to improve the lipid profile by increasing high-
density lipoproteins and decreasing low-density lipopro-the plasma SHBG concentration [8–10]. Ginsburg et al
[2] reported higher levels of SHBG in women with teins [15], the WHI did not find an overall benefit among
those receiving both estrogen and progesterone [6]. Re-ESRD than in control women who were not taking estro-
gen replacement (67 nmol/L vs. 42 nmol/L), and the sults from the ongoing WHI trial assessing estrogen alone
among women without an intact uterus are not yet avail-concentrations of SHBG did not change within 24 hours
after oral estrogen. In a longer trial of oral estradiol, 2 able. The risks and benefits of HRT among women with
ESRD are even less clear. Women with ESRD have amg/day for 8 weeks in women with ESRD, the SHBG
increased from 62 to 95 nmol/L; however, this study did markedly increased fracture risk [16], and although it has
not been studied, it is possible that estrogen replacementnot have a comparison population [11]. In the current
study, comparison of the effect of oral estradiol adminis- could also improve the fracture risk in this population.
In addition, women with ESRD have markedly abnormaltration on the concentration of SHBG was not possible,
as SHBG was not measured at baseline. It is possible lipid values [17, 18] that improve with estrogen replace-
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and metabolism in postmenopausal women with end-stage renalment [11]. The effects of estrogen on cardiovascular dis-
disease. J Clin Endocrinol Metab 81:4414–4417, 1996
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with chronic renal failure. Steroids 26:508–515, 1975of the lipid profile may have a relatively greater benefit. 4. Port F, Ragheb N, Schwartz A, et al: Neoplasms in dialysis
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5. Lim V, Henriquez C, Sievertsen G, et al: Ovarian function intigations in women with ESRD should use lower doses of chronic renal failure: Evidence suggesting hypothalamic anovula-
tion. Ann Int Med 93:21–27, 1980estrogen than used in women with normal renal function.
6. Risks and benefits of estrogen plus progestin in healthy post-
menopausal women: Principal results from the Women’s Health
Initiative randomized controlled trial. JAMA 288:321–333, 2002CONCLUSION 7. Vree TB, Timmer CJ: Enterohepatic cycling and pharmacokinetics
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10. Stomati M, Hartmann B, Spinetti A, et al: Effects of hormonalbe of value in selected postmenopausal women with end-
replacement therapy on plasma sex hormone-binding globulin,
stage renal disease receiving HRT. It is likely that any androgen and insulin-like growth factor-1 levels in postmenopausal
women. J Endocrinol Invest 19:535–541, 1996benefit would be relative to the blood concentration and
11. Ginsburg ES, Walsh B, Greenberg L, et al: Effects of estrogennot the actual dose, and there may be potential harm replacement therapy on the lipoprotein profile in postmenopausal
women with ESRD. Kidney Int 54:1344–1350, 1998in having excessively high blood concentrations. Future
12. Daly E, Vessey M, Hawkins M, et al: Risk of venous thromboem-studies should address whether dose modifications of
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estrogen are necessary among women with chronic kid- 980, 1996
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